Literature DB >> 28425048

Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Vera C Keil1, Bogdan Pintea2, Gerrit H Gielen3, Susanne Greschus1, Rolf Fimmers4, Jürgen Gieseke1,5, Matthias Simon2,6, Hans H Schild1, Dariusch R Hadizadeh7.   

Abstract

Current biopsy planning based on contrast-enhanced T1W (CET1W) or FLAIR sequences frequently delivers biopsy samples that are not in concordance with the gross tumor diagnosis. This study investigates whether the quantitative information of transfer constant Ktrans maps derived from T1W dynamic contrast-enhanced MRI (DCE-MRI) can help enhance the quality of biopsy target selection in glioma. 28 patients with suspected glioma received MRI including DCE-MRI and a standard neuronavigation protocol of 3D FLAIR- and CET1W data sets (0.1 mmol/kg gadobutrol) at 3.0 T. After exclusion of five cases with no Ktrans-elevation, 2-6 biopsy targets were independently selected by a neurosurgeon (samples based on standard imaging) and a neuroradiologist (samples based on kinetic parameter Ktrans) per case and tissue samples corresponding to these targets were collected by a separate independent neurosurgeon. Standard technique and Ktrans-based samples were rated for diagnostic concordance with the gross tumor resection reference diagnosis (67 WHO IV; 24 WHO III and II) by a neuropathologist blinded for selection mode. Ktrans-based sample targets differed from standard technique sample targets in 90/91 cases. More Ktrans-based than standard imaging-based samples could be extracted. Diagnoses from Ktrans-based samples were more frequently concordant with the reference gross tumor diagnoses than those from standard imaging-based samples (WHO IV: 30/39 vs. 11/20; p = 0.08; WHO III/II: 12/13 vs. 6/11; p = 0.06). In 4/5 non-contrast-enhancing gliomas, Ktrans-based selection revealed significantly more accurate samples than standard technique sample-selection (10/12 vs. 2/8 samples; p = 0.02). If Ktrans elevation is present, Ktrans-based biopsy targeting provides significantly more diagnostic tissue samples in non-contrast-enhancing glioma than selection based on CET1W and FLAIR-weighted images alone.

Entities:  

Keywords:  Benefit; Biopsy targeting; DCE-MRI; Glioma; Ktrans; Selection

Mesh:

Substances:

Year:  2017        PMID: 28425048     DOI: 10.1007/s11060-017-2424-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  46 in total

Review 1.  The role of blood-brain barrier permeability in brain tumor imaging and therapeutics.

Authors:  James M Provenzale; Srinivasan Mukundan; Mark Dewhirst
Journal:  AJR Am J Roentgenol       Date:  2005-09       Impact factor: 3.959

2.  Influence of partial volume on venous output and arterial input function.

Authors:  I van der Schaaf; E-J Vonken; A Waaijer; B Velthuis; M Quist; T van Osch
Journal:  AJNR Am J Neuroradiol       Date:  2006-01       Impact factor: 3.825

3.  Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density.

Authors:  Oliver Ganslandt; Andreas Stadlbauer; Rudolf Fahlbusch; Kyosuke Kamada; Rolf Buslei; Ingmar Blumcke; Ewald Moser; Christopher Nimsky
Journal:  Neurosurgery       Date:  2005-04       Impact factor: 4.654

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?

Authors:  Zoé Pedeutour-Braccini; Fanny Burel-Vandenbos; Catherine Gozé; Coralie Roger; Audrey Bazin; Valérie Costes-Martineau; Hugues Duffau; Valérie Rigau
Journal:  Virchows Arch       Date:  2015-01-21       Impact factor: 4.064

6.  Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis.

Authors:  Cher Heng Tan; Brian Paul Hobbs; Wei Wei; Vikas Kundra
Journal:  AJR Am J Roentgenol       Date:  2015-04       Impact factor: 3.959

7.  Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy.

Authors:  B C Son; M C Kim; B G Choi; E N Kim; H M Baik; B Y Choe; S Naruse; J K Kang
Journal:  Acta Neurochir (Wien)       Date:  2001       Impact factor: 2.216

8.  Stereotactic biopsy in gliomas guided by 3-tesla 1H-chemical-shift imaging of choline.

Authors:  Elvis J Hermann; Elke Hattingen; Joachim K Krauss; Gerhard Marquardt; Ulrich Pilatus; Kea Franz; Matthias Setzer; Thomas Gasser; Dominique S Tews; Friedhelm E Zanella; Volker Seifert; Heinrich Lanfermann
Journal:  Stereotact Funct Neurosurg       Date:  2008-09-15       Impact factor: 1.875

9.  Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.

Authors:  K Roessler; B Gatterbauer; A Becherer; M Paul; K Kletter; D Prayer; R Hoeftberger; J Hainfellner; S Asenbaum; E Knosp
Journal:  Minim Invasive Neurosurg       Date:  2007-10

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  1 in total

Review 1.  Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

Authors:  Whitney B Pope; Garth Brandal
Journal:  Q J Nucl Med Mol Imaging       Date:  2018-04-26       Impact factor: 2.346

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.